Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU)

This real-world study tracks the safety and clinical outcomes of patients who have received the EVOQUE transcatheter tricuspid valve replacement system across European medical centers. The tricuspid valve is on the right side of the heart; when it leaks severely, the EVOQUE device can replace it without open heart surgery. **You may be eligible if:** - Your heart team has already decided that you are a suitable candidate for transcatheter tricuspid valve replacement with the EVOQUE system, based on the current approved guidelines - You are willing to attend follow-up appointments - You are able to provide written informed consent **You may NOT be eligible if:** - You are currently enrolled in another interventional drug, biologic, or device clinical trial that has not yet finished - You are considered a vulnerable patient unable to make independent decisions Talk to your doctor to see if this trial is right for you.